report
extens
structureact
relationship
studi
novel
iiib
inhibitor
purin
deriv
potent
screen
hit
serv
suitabl
start
point
thorough
investig
posit
posit
purin
scaffold
bear
small
substitu
maintain
inhibitori
activ
posit
open
extens
modif
accommod
even
substitut
phenyl
ring
without
loss
iiib
inhibitori
activ
empir
observ
nice
correl
result
dock
studi
suggest
posit
direct
toward
solut
provid
necessari
space
interact
remot
residu
enzym
wherea
caviti
around
posit
strictli
limit
obtain
compound
also
subject
antivir
screen
panel
ssrna
virus
report
extens
structureact
relationship
studi
novel
iiib
inhibitor
purin
deriv
potent
screen
hit
serv
suitabl
start
point
thorough
investig
posit
posit
purin
scaffold
bear
small
substitu
maintain
inhibitori
activ
posit
open
extens
modif
accommod
even
substitut
phenyl
ring
without
loss
iiib
inhibitori
activ
empir
observ
nice
correl
result
dock
studi
suggest
posit
direct
toward
solut
provid
necessari
space
interact
remot
residu
enzym
wherea
caviti
around
posit
strictli
limit
obtain
compound
also
subject
antivir
screen
panel
ssrna
virus
publish
elsevi
ltd
phosphatidylinositol
catalyz
transfer
phosphat
atp
posit
phosphatidylinositol
result
format
phosphatidylinositol
import
phosphoinositid
involv
numer
cellular
process
vesicular
bud
membran
dynam
apart
signal
role
also
serv
crucial
intermedi
synthesi
phosphoinositid
includ
phosphatidylinositol
pi
phosphatidylinositol
pi
mammalian
cell
contain
four
differ
isoform
catalogu
class
ii
iia
iib
class
iii
iiia
iiib
member
class
iii
proven
implic
replic
variou
ss
rna
virus
specif
virusencod
protein
abl
recruit
misus
produc
highli
phosphoryl
membran
compart
serv
base
replic
complex
particular
iiib
known
indispens
replic
number
virus
picornavirida
famili
includ
common
human
viral
pathogen
rhinovirus
enterovirus
furthermor
enzym
implic
replic
coronavirus
repres
sarscov
addit
isoform
class
iii
famili
iiib
iiia
shown
necessari
host
factor
involv
life
cycl
hepat
c
viru
recent
sever
group
identifi
new
inhibitor
class
ii
select
inhibitor
iiia
iiib
furthermor
crystal
structur
iia
iib
iiib
solv
last
year
thu
allow
optim
inhibitor
effici
select
gener
two
distinct
type
select
iiib
inhibitor
introduc
fig
firstli
compound
regard
deriv
possess
fivememb
central
core
connect
aromat
side
chain
contrast
second
type
iiib
inhibitor
archetyp
exampl
character
bicycl
central
core
similar
aromat
sidechain
within
studi
use
purin
deriv
sever
structur
relat
bicycl
potenti
analog
latter
group
major
goal
complet
structureact
relationship
studi
understand
role
methyl
substitu
central
purin
core
although
initi
result
indic
purin
analog
approxim
six
time
less
activ
parent
compound
decid
use
structur
pattern
explor
mainli
potenti
substitut
posit
easi
access
vast
varieti
deriv
explor
sar
start
prepar
deriv
serv
start
materi
treat
nucleophil
substitut
follow
hydrochlorid
format
gave
desir
analog
depict
scheme
synthesi
deriv
start
commerci
avail
respect
nucleophil
displac
follow
format
moieti
furnish
key
intermedi
treatment
compound
morpholin
convers
hydrochlorid
salt
ether
hcl
ch
cl
afford
desir
compound
scheme
subsequ
sar
purin
deriv
began
variat
substitu
posit
h
ch
isopropyl
cyclohexenyl
cyclohexanyl
etc
use
builtup
strategi
similar
procedur
previous
report
us
other
start
compound
prepar
three
step
includ
reaction
give
deriv
imidazol
ringclosur
reaction
microwav
irradi
yield
compound
nucleophil
replac
chlorin
atom
morpholin
similar
reaction
sequenc
use
prepar
compound
bear
hydrogen
posit
case
directli
prepar
purin
deriv
one
step
reaction
microwav
irradi
chlorin
atom
replac
amin
afford
analog
compound
also
util
subsequ
prepar
deriv
obtain
two
stepsiron
iii
chloridesilica
gelmedi
imidazol
ring
format
subsequ
nucleophil
displac
chlorin
posit
purin
skeleton
scheme
compound
also
easili
convert
analog
palladiumcatalyz
hydrogen
aryl
member
seri
prepar
deriv
obtain
lithiat
lda
follow
quench
result
lithiat
speci
import
precursor
hand
small
set
deriv
prepar
scheme
tabl
compound
treat
phenylacetylen
classic
sonogashira
condit
afford
compound
furthermor
compound
subject
catalyt
hydrogen
reduct
respect
provid
deriv
good
yield
depict
scheme
lithiat
strategi
also
use
prepar
deriv
case
excess
lda
enabl
direct
prepar
deriv
subsequ
easili
transform
analog
nucleophil
substitut
use
sodium
methoxid
methanol
scheme
contrast
onepot
lithiat
compound
follow
addit
dmf
reduct
result
aldehyd
led
hydroxymethyl
deriv
convert
desir
final
compound
nucleophil
displac
chlorin
atom
posit
seri
final
prepar
perform
treatment
diamin
trifluoroacet
anhydrid
follow
heat
pyridin
dioxan
mixtur
led
deriv
compound
convert
target
compound
tri
dimethylamino
phosphonium
hexafluorophosph
bop
catalyz
amin
reaction
second
part
work
focus
synthesi
seri
compound
modifi
posit
firstli
simplifi
deriv
hydrogen
atom
posit
prepar
synthesi
compound
accomplish
start
compound
procedur
similar
use
compound
consist
imidazol
construct
follow
amino
sidechain
instal
desir
product
obtain
good
overal
yield
whole
seri
deriv
prepar
via
crucial
intermedi
prepar
start
diaminopyrimidin
deriv
tabl
case
convent
heat
provid
better
yield
coupl
product
microwaveassist
builtup
procedur
subsequ
closur
imidazol
ring
microwav
condit
afford
complex
mixtur
compound
partial
fulli
acetyl
amino
group
posit
therefor
crude
mixtur
heat
acid
condit
led
desir
intermedi
yield
final
obtain
nucleophil
substitut
similar
fashion
previou
case
yield
compound
serv
suitabl
start
materi
also
prepar
iodo
deriv
acquir
two
success
stepsiodin
introduct
via
sandmey
reaction
subsequ
nucleophil
displac
chlorin
posit
compound
serv
start
materi
prepar
small
librari
compound
various
modifi
posit
scheme
tabl
aromat
heteroaromat
substitu
instal
suzuki
coupl
reaction
alkyn
introduc
sonogashira
crosscoupl
cyano
deriv
obtain
palladiumcatalyz
reaction
bu
sncn
ome
deriv
prepar
nucleophil
displac
iodin
sodium
methoxid
final
homoderiv
parent
tabl
compound
prepar
compound
substitu
easili
prepar
buildup
procedur
three
step
scheme
effect
compound
iiib
iiia
measur
use
adpglo
assay
compound
exert
minim
effect
iiia
wherea
inhibitori
activ
iiib
strongli
depend
substitut
investig
posit
initi
measur
inhibit
lm
subsequ
ic
valu
residu
activ
lower
control
data
clearli
show
two
trend
tabl
firstli
substitut
posit
led
decreas
inhibitori
activ
comparison
parent
methyl
deriv
posit
open
small
substitu
besid
methyl
deriv
deriv
exert
mediocr
inhibitori
activ
bigger
substitu
result
complet
loss
inhibitori
activ
secondli
observ
interest
structureact
relationship
regard
posit
small
substitu
eg
amino
nitril
acetylen
group
toler
growth
substitu
activ
gener
drop
interestingli
deriv
hydrogenbond
acceptor
group
metaor
parasubstitu
phenyl
ring
compound
regain
inhibitori
activ
suggest
format
novel
interact
ligand
enzym
other
abl
crystal
iiib
complex
inhibitor
atp
prepar
letter
allow
deeper
understand
observ
structureact
relationship
perform
seri
dock
studi
base
recent
publish
structur
data
order
elucid
phenomena
remov
nitrogen
atom
posit
accompani
signific
drop
activ
compound
easili
explain
miss
hydrogen
bond
core
inhibitor
amid
moieti
steric
hindranc
addit
hydrogen
atom
caus
addit
distort
amino
sidechain
loss
anoth
hydrogen
contact
carbonyl
moieti
support
fig
dock
result
nice
explain
also
observ
lack
activ
deriv
caus
limit
space
bind
caviti
appropri
accommod
methyl
group
support
fig
partial
loss
activ
compound
addit
nitrogen
posit
could
explain
repuls
electron
pair
nitrogen
atom
occupi
small
caviti
carbonyl
group
support
fig
data
also
indic
carbonyl
oxygen
amid
group
attach
phenyl
substitu
posit
deriv
easili
form
hydrogen
bond
enhanc
inhibitori
effect
inhibitor
fig
similarli
compound
easili
accommod
posit
carbonyl
moieti
close
proxim
although
altern
bind
mode
amid
hydrogen
interact
carbonyl
group
might
also
possibl
accord
dock
result
support
fig
apart
enzymat
studi
also
evalu
antivir
activ
compound
panel
ssrna
virus
contain
coxsackieviru
human
rhinoviru
hrvm
hepat
c
viru
hcv
seri
antivir
activ
larg
correl
observ
inhibitori
activ
iiib
thu
methyl
deriv
analog
exert
signific
activ
antivir
screen
seri
deriv
small
substitu
exert
gener
lower
antivir
activ
compound
seri
highest
antivir
activ
whole
seri
observ
metaand
parasubstitut
deriv
surpris
howev
observ
antivir
effect
test
virus
compound
inhibit
iiib
also
deriv
eg
might
attribut
offtarget
effect
cytotox
conclus
prepar
seri
novel
purin
deriv
order
studi
effect
substitu
posit
inhibitori
activ
iiib
studi
clearli
prove
posit
suitabl
extens
modif
methyl
group
optimum
hand
opposit
side
purin
scaffold
posit
decor
variou
substitu
although
observ
signific
drop
inhibitori
activ
deriv
simpl
aromat
ring
analog
bear
appropri
substitut
phenyl
exert
restor
inhibitori
activ
titl
enzym
also
prove
potent
antivir
screen
variou
ssrna
virus
